These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 27460824)

  • 1. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
    Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
    Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A method to reduce ancestry related germline false positives in tumor only somatic variant calling.
    Halperin RF; Carpten JD; Manojlovic Z; Aldrich J; Keats J; Byron S; Liang WS; Russell M; Enriquez D; Claasen A; Cherni I; Awuah B; Oppong J; Wicha MS; Newman LA; Jaigge E; Kim S; Craig DW
    BMC Med Genomics; 2017 Oct; 10(1):61. PubMed ID: 29052513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
    Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
    PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized genomic analyses for cancer mutation discovery and interpretation.
    Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
    Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.
    Ghazani AA; Oliver NM; St Pierre JP; Garofalo A; Rainville IR; Hiller E; Treacy DJ; Rojas-Rudilla V; Wood S; Bair E; Parello M; Huang F; Giannakis M; Wilson FH; Stover EH; Corsello SM; Nguyen T; Rana HQ; Church AJ; Lowenstein C; Cibulskis C; Amin-Mansour A; Heng J; Brais L; Santos A; Bauer P; Waldron A; Lo P; Gorman M; Lydon CA; Welch M; McNamara P; Gabriel S; Sholl LM; Lindeman NI; Garber JE; Joffe S; Van Allen EM; Gray SW; Ja Nne PA; Garraway LA; Wagle N
    Genet Med; 2017 Jul; 19(7):787-795. PubMed ID: 28125075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
    Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
    J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
    Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
    J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of candidate genes encoding tumor-specific neoantigens in early- and late-stage colon adenocarcinoma.
    Wang C; Xue W; Zhang H; Fu Y
    Aging (Albany NY); 2021 Jan; 13(3):4024-4044. PubMed ID: 33428592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
    Heydt C; Rehker J; Pappesch R; Buhl T; Ball M; Siebolts U; Haak A; Lohneis P; Büttner R; Hillmer AM; Merkelbach-Bruse S
    Sci Rep; 2020 Jul; 10(1):11387. PubMed ID: 32647293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeted gene sequencing panels: applicability for neoantigen profiling of colon and rectal adenocarcinoma].
    Kanygina AV; Sharova EI; Sultanov RI; Schelygin YA; Doludin YV; Kostryukova ES; Generozov EV
    Biomed Khim; 2018 Nov; 64(6):517-524. PubMed ID: 30632980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
    You YN; Borras E; Chang K; Price BA; Mork M; Chang GJ; Rodriguez-Bigas MA; Bednarski BK; Meric-Bernstam F; Vilar E
    Dis Colon Rectum; 2019 Apr; 62(4):429-437. PubMed ID: 30730459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
    Campesato LF; Barroso-Sousa R; Jimenez L; Correa BR; Sabbaga J; Hoff PM; Reis LF; Galante PA; Camargo AA
    Oncotarget; 2015 Oct; 6(33):34221-7. PubMed ID: 26439694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
    Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
    Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
    Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligogenic germline mutations identified in early non-smokers lung adenocarcinoma patients.
    Renieri A; Mencarelli MA; Cetta F; Baldassarri M; Mari F; Furini S; Piu P; Ariani F; Dragani TA; Frullanti E
    Lung Cancer; 2014 Aug; 85(2):168-74. PubMed ID: 24954872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Alteration During Metastasis of Lung Adenocarcinoma.
    Tan Q; Cui J; Huang J; Ding Z; Lin H; Niu X; Li Z; Wang G; Luo Q; Lu S
    Cell Physiol Biochem; 2016; 38(2):469-86. PubMed ID: 26828653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
    Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
    BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
    Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
    JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
    Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.
    LaDuca H; Farwell KD; Vuong H; Lu HM; Mu W; Shahmirzadi L; Tang S; Chen J; Bhide S; Chao EC
    PLoS One; 2017; 12(2):e0170843. PubMed ID: 28152038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.